These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 15336599

  • 1. The flurbiprofen derivatives HCT1026 and HCT1027 inhibit bone resorption by a mechanism independent of COX inhibition and nitric oxide production.
    Idris AI, Del Soldato P, Ralston SH, van't Hof RJ.
    Bone; 2004 Sep; 35(3):636-43. PubMed ID: 15336599
    [Abstract] [Full Text] [Related]

  • 2. The nitrosylated flurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action.
    Idris AI, Ralston SH, van't Hof RJ.
    Eur J Pharmacol; 2009 Jan 14; 602(2-3):215-22. PubMed ID: 19046964
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026).
    Armour KJ, van 't Hof RJ, Armour KE, Torbergsen AC, Del Soldato P, Ralston SH.
    Arthritis Rheum; 2001 Sep 14; 44(9):2185-92. PubMed ID: 11592384
    [Abstract] [Full Text] [Related]

  • 4. Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity.
    van't Hof RJ, Ralston SH.
    J Bone Miner Res; 1997 Nov 14; 12(11):1797-804. PubMed ID: 9383684
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Opposite effects of flurbiprofen and the nitroxybutyl ester of flurbiprofen on apoptosis in cultured guinea-pig gastric mucous cells.
    Johal K, Hanson PJ.
    Br J Pharmacol; 2000 Jun 14; 130(4):811-8. PubMed ID: 10864887
    [Abstract] [Full Text] [Related]

  • 11. The effects and metabolic fate of nitroflurbiprofen in healthy volunteers.
    Zacharowski P, Zacharowski K, Donnellan C, Johnston A, Vojnovic I, Forte P, Del Soldato P, Benjamin N, O'Byrne S.
    Clin Pharmacol Ther; 2004 Oct 14; 76(4):350-8. PubMed ID: 15470334
    [Abstract] [Full Text] [Related]

  • 12. Herbal formulation, Yukmi-jihang-tang-Jahage, regulates bone resorption by inhibition of phosphorylation mediated by tyrosine kinase Src and cyclooxygenase expression.
    Jin UH, Kim DI, Lee TK, Lee DN, Kim JK, Lee IS, Kim CH.
    J Ethnopharmacol; 2006 Jul 19; 106(3):333-43. PubMed ID: 16513308
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of cyclooxygenase-2 down-regulates osteoclast and osteoblast differentiation and favours adipocyte formation in vitro.
    Kellinsalmi M, Parikka V, Risteli J, Hentunen T, Leskelä HV, Lehtonen S, Selander K, Väänänen K, Lehenkari P.
    Eur J Pharmacol; 2007 Oct 31; 572(2-3):102-10. PubMed ID: 17632097
    [Abstract] [Full Text] [Related]

  • 14. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
    Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, O'Reilly T, Lane H, Susa M.
    Bone; 2004 Nov 31; 35(5):1144-56. PubMed ID: 15542040
    [Abstract] [Full Text] [Related]

  • 15. Osteocytes subjected to fluid flow inhibit osteoclast formation and bone resorption.
    Tan SD, de Vries TJ, Kuijpers-Jagtman AM, Semeins CM, Everts V, Klein-Nulend J.
    Bone; 2007 Nov 31; 41(5):745-51. PubMed ID: 17855178
    [Abstract] [Full Text] [Related]

  • 16. Differential effects of the nonsteroidal antiinflammatory drug flurbiprofen and its nitric oxide-releasing derivative, nitroflurbiprofen, on prostaglandin E(2), interleukin-1beta, and nitric oxide synthesis by activated microglia.
    Ajmone-Cat MA, Nicolini A, Minghetti L.
    J Neurosci Res; 2001 Nov 15; 66(4):715-22. PubMed ID: 11746392
    [Abstract] [Full Text] [Related]

  • 17. Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors.
    Van 't Hof RJ, Idris AI, Ridge SA, Dunford J, Greig IR, Ralston SH.
    J Bone Miner Res; 2004 Oct 15; 19(10):1651-60. PubMed ID: 15355560
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and biological evaluation of 3,4-diphenyl-1,2,5-oxadiazole-2-oxides and 3,4-diphenyl-1,2,5-oxadiazoles as potential hybrid COX-2 inhibitor/nitric oxide donor agents.
    Velázquez C, Rao PN, McDonald R, Knaus EE.
    Bioorg Med Chem; 2005 Apr 15; 13(8):2749-57. PubMed ID: 15781386
    [Abstract] [Full Text] [Related]

  • 19. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.
    El Hajj Dib I, Gallet M, Mentaverri R, Sévenet N, Brazier M, Kamel S.
    Eur J Pharmacol; 2006 Dec 03; 551(1-3):27-33. PubMed ID: 17049513
    [Abstract] [Full Text] [Related]

  • 20. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
    Väänänen K.
    Adv Drug Deliv Rev; 2005 May 25; 57(7):959-71. PubMed ID: 15876398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.